Recent Advances in Anti-HCV, Anti-HBV and Anti-Flavivirus Agents, 2nd Edition
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 270
Special Issue Editor
Interests: medicinal chemistry; antiviral agents; anticancer agents; trypanocidal agents; anti-HBV drugs; anti-HCV drugs; anti-influenza A agents; anti-flavivirus agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the beginning of human civilization, viral infections have been part of human life and still represent one of the heaviest burdens for humans and society, with a huge devastating socioeconomic impact. The global burden of viral hepatitis remains substantial despite advances in antiviral therapy and effective vaccines. Mortality related to hepatitis B virus and hepatitis C virus infections is among the top four global infectious diseases, together with human immunodeficiency virus infection, malaria, and tuberculosis. According to the World Health Organization (WHO), for viral-infection-related diseases such as hepatitis B, the achievement of a suitable treatment still has a long way to go. On the other hand, the flaviviruses, Dengue (DENV), Yellow fever (YFV), Zika (ZIKV) and West Nile (WNV) are high-priority targets for drug discovery as they are re-emerging global pathogens with no clinically approved specific therapy (according to the WHO). WNV and YFV are among the most dangerous flaviviruses, having mortality rates up to 30%. Moreover, the emergence of drug resistance that threatens the efficacy of successful therapies used today against HCV makes the discovery and development of antiviral agents an unmet global need. Urged by this global crisis, the field has been involved in an unprecedented endeavour to enhance established antiviral strategies and develop novel and innovative approaches for new classes of antiviral agents targeting different and critical for the virus life cycle pathways, including viral and host factors and new antiviral modalities.
In this Special Issue entitled: “Recent Advances in Anti-HCV, Anti-HBV and Anti-Flavivirus Agents, 2nd Edition”, we are inviting the submission of original research articles, letters, and/or reviews from academia, research institutes, not-for-profit organizations, or industries working over the identification, synthesis, and evaluation of direct-acting anti-HCV, anti-HBV, and anti-flavivirus agents or host-targeting agents which inhibit viral replication or pathogenesis (HCV, HBV, and flaviviruses). Furthermore, papers on mechanistic studies of new small organic molecules, metal complexes, and natural products, as well as studies on drug resistance, in silico designs of anti-HCV, anti-HBV, and anti-Flavivirus agents, or HCV, HBV, and flavivirus target validation studies are also welcome for submissions.
Dr. Grigoris Zoidis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- medicinal chemistry of anti-HCV, anti-HBV and anti-flavivirus agents
- synthesis
- structure activity relationships (SAR)
- antiviral drug discovery
- HBV
- HCV
- Dengue (DENV)
- Yellow Fever (YFV)
- West Nile (WNV)
- Zika (ZIKV)
- mechanism of action
- drug targets
- in silico studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
